Option chain shows key data for Journey Medical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Journey Medical.

Journey Medical (NASDAQ:DERM) Stock, Option Chain

Journey Medical

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

A Different Picture

News

Movers

DERM

Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the treatment of rosacea.

What&#39;s Going On With Journey Medical Stock Today?

AGRI

AILE

BCDA

CELH

CLEU

CMLS

CRWD

EFSH

ENSV

ESPR

FCEL

GERN

GMGI

HOUS

HOVR

ICCH

LENZ

MLGO

NISN

NVAX

OPRA

PERI

PRST

RENB

ROMA

SBFM

SIFY

SKYE

SMHI

SPEC

SYNX

TELL

THAR

TNXP

TPHS

VRAX

WETH

WLDS

Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

The Dow Jones index closed higher by over 475 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Journey Medical And 2 Other Stocks Under $4 Insiders Are Buying

Journey Medical Corporation - Common Stock

Journey Medical Corp

DermTech Inc

DermTech Inc Warrants(20/06/2022)

Dermapharm Holding SE

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

Dermisonics Inc

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 115 percent decrease over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $14.63 million which beat the analyst consensus estimate of $14.39 million by 1.68 percent. This is a 57.64 percent decrease over sales of $34.54 million the same period last year.

Earnings

Earnings Beats

Journey Medical Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $14.63M Beat $14.39M Estimate

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 127.9% to $3.1 during Monday's regular session. The company's market cap stands at $5.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) stock moved upwards by 58.24% to $21.3. The company's market cap stands at $53.1 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares increased by 44.04% to $66.36. The market value of their outstanding shares is at $862.2 million. </li>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock rose 24.27% to $23.96. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 23.42% to $1.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) shares moved upwards by 22.19% to $57.59. The market value of their outstanding shares is at $1.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 15.8% to $1.98 during Monday's regular session. The company's market cap stands at $10.7 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) stock declined by 15.6% to $7.12. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares declined by 15.57% to $12.1. The market value of their outstanding shares is at $497.2 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares decreased by 15.52% to $14.87. The market value of their outstanding shares is at $22.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 13.5% to $2.05. The company's market cap stands at $349.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock decreased by 13.3% to $5.35. The market value of their outstanding shares is at $110.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCRX

BSGM

CVKD

IART

IRON

NGNE

NUWE

OMIC

THRD

TVGN

XTLB

12 Health Care Stocks Moving In Monday's Intraday Session

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the <a href="https://www.benzinga.com/pressreleases/24/11/g41709594/journey-medical-corporation-announces-u-s-fda-approval-of-emrosi-minocycline-hydrochloride-extende">treatment of rosacea</a>.
What Happened: The FDA has approved Journey Medical&#8217;s Emrosi, formerly known as DFD-29, for the treatment of inflammatory lesions of rosacea in adults.&nbsp;
The approval was supported by positive data from the company&#8217;s two Phase 3 clinical trials, which met all co-primary and secondary endpoints. Journey Medical said Emrosi demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea, and placebo. 
Journey Medical announced that it&#8217;s in the process of completing the manufacturing of Emrosi for the U.S. market. The company expects initial supply of the drug to be available late in the&nbsp;first quarter&nbsp;or early in the&nbsp;second quarter&nbsp;of 2025.
&#8220;With approval from the FDA, Journey Medical is proud to deliver Emrosi, a unique treatment option for the millions of patients in the U.S. suffering from rosacea,&#8221; said Claude Maraoui, co-founder, president and CEO of Journey Medical.
&#8220;Rosacea is a difficult to treat skin condition and based on the favorable results from our Phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition. Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea.&#8221;
Journey Medical said it intends to commercialize Emrosi in the U.S. with its dermatology-focused commercial organization. The company aims to execute a launch strategy to help push Emrosi toward becoming the new oral standard of care for adult rosacea patients.
See Also:<a href="https://www.benzinga.com/general/biotech/24/11/41713478/jim-cramer-says-vertex-doing-lords-work-can-q3-earnings-outshine-bearish-charts"> Jim Cramer Says Vertex Doing &#8216;Lord&#8217;s Work&#8217;: Can Q3 Earnings Outshine Bearish Charts?</a>
DERM Price Action: <a href="http://benzinga.com/quote/derm">Journey Medical shares</a> were up 3.40% at $6.38 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

What's Going On With Journey Medical Stock Today?

General

Journey Medical shares are trading higher after the company announced the preparation of the U.S. launch of its FDA-approved rosacea drug Emrosi.

Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi&#x2122; (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd.
Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical, said, "With approval from the FDA, Journey Medical is proud to deliver Emrosi, a unique treatment option for the millions of patients in the U.S. suffering from rosacea. Rosacea is a difficult to treat skin condition and based on the favorable results from our Phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition. Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea. Journey Medical is committed to bringing cutting-edge innovation to patients with dermatological conditions and the healthcare professionals who treat them."
The approval of Emrosi is supported by positive data from Journey Medical's two Phase 3 clinical trials for the treatment of rosacea. The Phase 3 clinical trials met all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues. Emrosi demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea&#xAE; 40 mg capsules, and placebo for Investigator's Global Assessment treatment success as well as the reduction in total inflammatory lesion count in both studies.
Journey Medical is completing the manufacturing of Emrosi for the U.S. market and anticipates that initial supply will be available late in the first quarter or early in the second quarter of 2025. Journey Medical intends to commercialize Emrosi in the U.S. with its dermatology-focused commercial organization. In line with the approved label, Journey Medical will execute a launch strategy to drive Emrosi toward becoming a new oral standard of care for adult rosacea patients.
Srinivas Sidgiddi, M.D., Vice President, Research &amp; Development at Journey Medical, added, "Emrosi showed great efficacy and tolerability in the pivotal clinical trials, and we are tremendously grateful to the patients, physicians, investigators, and site coordinators who participated and contributed to this important approval milestone."

Government

Regulations

Journey Medical Prepares US Launch for FDA-Approved Rosacea Drug Emrosi

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea&#xAE;) in Healthy Subjects
With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea
New Drug Application for DFD-29 under review by FDA with PDUFA goal date of November 4, 2024

Biotech

Events

Journey Medical Presents DFD-29 Data At 44th Fall Clinical Dermatology Conference

Lake Street analyst Thomas Flaten initiates coverage on Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) with a Buy rating and announces Price Target of $9.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9

Rodman &amp; Renshaw initiates coverage on Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) with a Buy rating and announces Price Target of $9.

Rodman & Renshaw Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9

WIIM

Journey Medical shares are trading higher after the company reported better-than-expected Q2 revenue results.

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 63.04 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $14.855 million which beat the analyst consensus estimate of $13.880 million by 7.02 percent. This is a 13.49 percent decrease over sales of $17.172 million the same period last year.

Earnings Misses

Journey Medical Q2 2024 GAAP EPS $(0.17) Misses $(0.14) Estimate, Sales $14.855M Beat $13.880M Estimate

Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) with a Buy and announces $11 price target.

Roth MKM Reinstates Buy on Journey Medical, Announces $11 Price Target

Shares of Skye Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has <a href="https://www.benzinga.com/quote/SKYE/news">discontinued the program</a>.
Skye Bioscience shares tumbled 18.9% to $8.87 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares jumped 123% to $4.3001 following the completion of the company&#8217;s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) gained 79.8% to $0.7082 after the company was awarded a sub-contract worth up to C$48 million by Thales Canada for software development services.</li>
<li>Wearable Devices Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>) jumped 63% to $0.5547. Wearable Devices reported the successful completion of its first phase of integration with Qualcomm&#8217;s Snapdragon Spaces&#x2122;, extended reality (XR) Developer Platform.</li>
<li>New Horizon Aircraft Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) gained 45.1% to $1.0450 after declining around 8% on Friday.</li>
<li>ICC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCH#NASDAQ">ICCH</a>) jumped 43% to $22.03. Mutual Capital Group announced plans to acquire ICC Holdings, Inc. for $23.50 per share in a $73.8 million transaction.</li>
<li>Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) shares gained 32.3% to $0.5623 after jumping over 15% on Friday.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 28.6% to $283.00.</li>
<li>Renovaro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) rose 25.6% to $1.62.</li>
<li>Wetouch Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) surged 25% to $2.23.</li>
<li>Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) gained 24% to $5.83.</li>
<li>Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) surged 22% to $16.83.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) rose 20.2% to $5.33.</li>
<li>Ivanhoe Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) gained 18% to $10.74.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) jumped 17.5% to $5.58.</li>
<li>Silynxcom Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#NYSE">SYNX</a>) surged 17% to $2.62.</li>
<li>Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) jumped 16.6% to $0.4960 after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) gained 15% to $0.1070 after the company was awarded a new US patent titled &#8216;Automated Growing Systems.&#8217;</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) rose 13.6% to $0.9869. FuelCell Energy reported a second-quarter fiscal 2024 revenue decline of 42% year-over-year to $22.42 million, beating the consensus of $21.35 million.</li>
<li>Cactus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) gained 13.6% to $53.19.</li>
<li>Tellurian Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NASDAQ">TELL</a>) gained 12.8% to $0.8448.</li>
<li>SEACOR Marine Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMHI#NYSE">SMHI</a>) gained 12.1% to $13.26.</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) shares rose 10.9% to $0.0988 after surging 17% on Friday.</li>
<li>KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) gained 9.8% to $107.63 after it was announced the company will join the S&amp;P 500.</li>
<li>Diamond Offshore Drilling, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DO#NYSE">DO</a>) climbed 9.8% to $15.30 after Noble announced an agreement to acquire the company.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) gained 8.8% to $379.95 after it was announced the company will join the S&amp;P 500.</li>
<li>LENZ Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) rose 8.2% to $16.85.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) shares rose 7.6% to $3.6302 after the company said it has established a daily supply capacity of over 20 million eggs.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) gained 7.5% to $3.01.</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) gained 6.8% to $29.66 following a report indicating Elliott Investment Management has built a stake in the company.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) rose 5.9% to $4.8592. Barclays initiated coverage on Geron with an Overweight rating and announced a price target of $9.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) dipped 32.5% to $0.4828.</li>
<li>Baijiayun Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) fell 32% to $3.7001</li>
<li>Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares fell 31.4% to $0.3830.</li>
<li>Tharimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) dipped 30% to $3.6051</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) fell 29.3% to $2.3550. Tonix Pharmaceuticals recently announced a 1-for-32 reverse stock split.</li>
<li>Enservco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENSV#NYSE">ENSV</a>) fell 29.3% to $0.1713 after the company announced the staff of NYSE Regulation determined to commence proceedings to delist its common stock.</li>
<li>Perion Network Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) shares fell 28.3% to $8.84 after the company cut its revenue outlook.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) fell 24.7% to $0.6249 after the company announced the voluntary delisting date of its ADS rights from Nasdaq.</li>
<li>SeaStar Medical Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) declined 23% to $4.22.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) fell 19.9% to $19.62</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 16.8% to $2.66 in pre-market trading after jumping 58% on Friday.</li>
<li>Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares fell 14.8% to $1.68.</li>
<li>Trinity Place Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPHS#NYSE">TPHS</a>) fell 14.7% to $0.1498 after jumping 45% on Friday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 13.1% to $24.53. On Friday, the stock traded lower as Roaring Kitty held a live stream and the company reported Q1 earnings.</li>
<li>Golden Matrix Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMGI#NASDAQ">GMGI</a>) declined 12.5% to $3.16.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 11.8% to $16.01.</li>
<li>Anywhere Real Estate Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOUS#NYSE">HOUS</a>) fell 10.6% to $3.4150.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell 10.6% to $10.11</li>
<li>BioCardia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares fell 10% to $3.35. On Friday, BioCardia announced it received approval from the United States Patent Office for its application entitled, "Radial and Transendocardial Delivery Catheter."</li>
<li>Cumulus Media Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) shares fell 7.6% to $2.9550 after jumping around 22% on Friday.</li>
<li>Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) fell 7.6% to $12.36. Compass Minerals International named Jeffrey Cathey as its new chief financial officer.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) fell 7% to $68.08.</li>
<li>Roma Green Finance Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) shares declined 6% to $0.4683. Roma Green Finance filed for offering in a best efforts self-underwritten offering of up to 3.6 million of ordinary shares.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39249956/flexshopper-and-3-other-stocks-under-5-insiders-are-buying">FlexShopper And 3 Other Stocks Under $5 Insiders Are Buying</a>

Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.23) by 130.43 percent. The company reported quarterly sales of $13.000 million which missed the analyst consensus estimate of $14.098 million by 7.79 percent. This is a 6.44 percent increase over sales of $12.213 million the same period last year.

Journey Medical Q1 2024 Adj EPS $(0.53) Misses $(0.23) Estimate, Sales $13.000M Miss $14.098M Estimate

Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. &nbsp;
Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, said, "Joe has been an instrumental leader to our finance and accounting team for the past few years and it will be a seamless transition as he steps into the permanent CFO role. With more than 25 years of experience in the public and private sectors including the life sciences industry, Joe's in-depth financial and accounting knowledge and pharmaceutical experience are valuable assets to our company as we focus on our many upcoming milestones, including the potential approval of DFD-29 for the treatment of rosacea later this year. We look forward to Joe's continued contributions to Journey Medical."
Mr. Benesch has over 25 years of experience in all aspects of corporate financial leadership and reporting, technical accounting and controls, corporate controllership, regulatory and public company compliance, treasury and pharmaceutical company operations. Prior to joining Journey Medical, Mr. Benesch previously served as the Principal Accounting Officer, Vice President and Corporate Controller of Teligent Pharma Inc., a specialty generic pharmaceutical company, and Corporate Controller of Torrent Pharmaceuticals, a U.S. subsidiary of the Torrent Group, a multinational pharmaceutical company. Before joining Torrent, he held senior financial management positions of increasing responsibility from Corporate Controller to Vice President of Finance at Savient Pharmaceuticals, Adare Pharmaceuticals and Edenbridge Pharmaceuticals. Mr. Benesch began his career in the public accounting sector at Baker Tilly Virchow Krause, LLP, and Ernst and Young working with a diverse client base. Mr. Benesch is a graduate of Wilkes University where he earned a BA in accounting and is a Certified Public Accountant.
"I am privileged and honored to continue to lead our finance organization as we seek to drive sustainable value creation for the Company and our shareholders while helping the many patients treated with our dermatology products," said Mr. Benesch.

Management

Journey Medical Corporation Appoints Joseph Benesch As Chief Financial Officer, Effective April 26, 2024

The Dow Jones index closed higher by over 475 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Retractable Technologies </h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvp#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/quote/RVP/analyst-ratings"> acquired a total of 5,096 shares </a> an average price of $1.18. To acquire these shares, it cost around $6,024.</li>
<li>What&rsquo;s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
<h3>Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cia#NYSE">CIA</a>) Director James Keith Morgan <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,899 shares at </a> at an average price of $2.11. To acquire these shares, it cost around $12,469.</li>
<li>What&rsquo;s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/03/37975793/walgreens-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-cal"> Walgreens Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>
<h3>Journey Medical </h3>
<ul>
<li>The Trade: Journey Medical Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/derm#NASDAQ">DERM</a>) Director Lindsay A MD Rosenwald <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 10,000 shares </a> at an average price of $3.04. The insider spent around $30,400 to buy those shares.</li>
<li>What&rsquo;s Happening: On March 21, Journey Medical posted a profit for the fourth quarter.</li>
<li>What Journey Medical Does: Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Shares of Westport Fuel Systems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wprt#NASDAQ">WPRT</a>) fell sharply during Tuesday&rsquo;s session after posting a wider-than-expected fourth-quarter loss.
Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.
Westport Fuel Systems shares dipped 9.9% to $6.52 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Stoke Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stok#NASDAQ">STOK</a>) shares gained 72.6% to $11.24 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) climbed 65% to $0.0581 after the company reported a year-over-year increase in fourth-quarter financial results.</li>
<li>OpGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opgn#NASDAQ">OPGN</a>) shares climbed 48.2% to $0.7039 after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) gained 43.2% to $3.1501. Mesoblast was notified by the U.S. FDA that available clinical data from Phase 3 trial appear sufficient to support BLA submission for Remestemcel-L in children with steroid-refractory acute graft versus host disease.</li>
<li>Praxis Precision Medicines Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prax#NASDAQ">PRAX</a>) gained 31.9% to $66.63 after the company reported results from a Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR.</li>
<li>Nuvation Bio Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nuvb#NYSE">NUVB</a>) climbed 24.4% to $2.80 after BTIG upgraded the stock from Neutral to Buy.</li>
<li>Check-Cap Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chek#NASDAQ">CHEK</a>) shares gained 24.3% to $2.40 after the company announced that it entered into a definitive Business Combination Agreement with Nobul AI.</li>
<li>Viking Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares climbed 23.3% to $85.29 after the company announced results from its Phase 1 multiple ascending dose clinical trial of an oral tablet formulation of VK2735.</li>
<li>Krispy Kreme, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnut#NASDAQ">DNUT</a>) gained 21.3% to $15.10 after the company and McDonald&#39;s expanded their partnership, with Krispy Kreme to provide donuts at McDonald&#39;s locations nationwide.</li>
<li>Journey Medical Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/derm#NASDAQ">DERM</a>) gained 19.9% to $3.50.</li>
<li>Akso Health Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahg#NASDAQ">AHG</a>) climbed 17.5% to $1.21.</li>
<li>9F Inc &ndash; ADR (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfu#NASDAQ">JFU</a>) gained 17% to $3.50.</li>
<li>Invivyd, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivvd#NASDAQ">IVVD</a>) gained 17% to $3.78. Morgan Stanley analyst Maxwell Skor upgraded Invivyd from Equal-Weight to Overweight and raised the price target from $4 to $10.</li>
<li>Sunnova Energy International Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nova#NYSE">NOVA</a>) shares gained 16.4% to $6.28 after the company announced that it will be the sole provider of solar and battery storage services in The Home Depot stores across the United States and its territories.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gwav#NASDAQ">GWAV</a>) climbed 16.3% to $0.18 after surging 24% on Monday. Greenwave Technology Solutions 13G filing showed Joseph Reda reported a 9.119% stake in the co as of March 22, 2024.</li>
<li>Reddit Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rddt#NYSE">RDDT</a>) climbed 15.8% to $69.26 amid post-IPO volatility.</li>
<li>Canopy Growth Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) shares gained 15.6% to $7.17.</li>
<li>Qurate Retail Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qrteb#NASDAQ">QRTEB</a>) climbed 13.7% to $4.40.</li>
<li>Natural Grocers by Vitamin Cottage Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ngvc#NYSE">NGVC</a>) climbed 13.4% to $19.25.</li>
<li>60 Degrees Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtp#NASDAQ">SXTP</a>) shares rose 9.8% to $0.2660 after dipping 10% on Monday.</li>
<li>Seagate Technology Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stx#NASDAQ">STX</a>) gained 9.2% to $96.33 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $73 to $115.</li>
<li>McCormick &amp; Company Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mkc#NYSE">MKC</a>) climbed 9% to $76.24 after the company reported better-than-expected first-quarter financial results.</li>
<li>IHS Holding Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihs#NYSE">IHS</a>) climbed 7.6% to $3.74.</li>
<li>Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) gained 5.8% to $182.65 amid reports suggest Italy has approached the company about electric truck production.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quhuo Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qh#NASDAQ">QH</a>) dipped 68.5% to $0.40.</li>
<li>NeuBase Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbse#NASDAQ">NBSE</a>) fell 51.8% to $0.48 after declining around 3% on Monday.</li>
<li>Cardlytics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdlx#NASDAQ">CDLX</a>) dipped 40.4% to $12.06 after the company announced a $150 million proposed convertible senior notes offering.</li>
<li>AppTech Payments Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apcx#NASDAQ">APCX</a>) fell 39.3% to $1.00 after the company priced its 2 million share offering at $1 per share.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares tumbled 27.6% to $0.037 after jumping around 30% on Monday.</li>
<li>Professional Diversity Network Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipdn#NASDAQ">IPDN</a>) fell 27.2% to $1.82.</li>
<li>Canoo Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goev#NASDAQ">GOEV</a>) shares fell 21.4% to $3.30.</li>
<li>GDS Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gds#NASDAQ">GDS</a>) fell 20.2% to $6.68 after the company reported fourth-quarter results, disclosed equity raise and new CEO for its international business.</li>
<li>Equillium Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eq#NASDAQ">EQ</a>) shares declined 20.1% to $1.95 following fourth-quarter results.</li>
<li>BYND Cannasoft Enterprises (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares fell 17.9% to $1.61.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) shares declined 17.9% to $14.78.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) shares dropped 17.8% to $2.08 after the company reported downbeat fourth-quarter results.</li>
<li>Etao International (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etao#NASDAQ">ETAO</a>) shares fell 14.7% to $4.35.</li>
<li>Tivic Health Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tivc#NASDAQ">TIVC</a>) fell 14.4% to $1.24 after posting fourth-quarter results.</li>
<li>Akebia Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akba#NASDAQ">AKBA</a>) shares dipped 9.5% to $2.00.</li>
<li>Graphjet Technology (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gti#NASDAQ">GTI</a>) fell 9.3% to $7.26.</li>
<li>Monte Rosa Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glue#NASDAQ">GLUE</a>) dipped 8.4% to $7.75.</li>
<li>Consol Energy Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ceix#NYSE">CEIX</a>) declined 8.1% to $79.36.</li>
<li>RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) fell 4% to $276.00. Telsey Advisory Group analyst Joseph Feldman reiterated RH with a Market Perform and maintained a $285 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37934560/ethereum-surpasses-3-600-dogwifhat-emerges-as-top-gainer"> Ethereum Surpasses $3,600; dogwifhat Emerges As Top Gainer</a>

Small Cap

Intraday Update

AKBA

APCX

BCAN

CDLX

CEIX

CHEK

CISS

DADA

DNUT

EGOX

ETAO

GLUE

GOEV

GWAV

IPDN

IVVD

MESO

MRNO

NBSE

NGVC

NOVA

NUVB

OPGN

PRAX

QRTEB

RDDT

STOK

SXTP

TIVC

TSLA

VKTX

WPRT

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock moved upwards by 71.8% to $11.16 during Tuesday's regular session. The company's market cap stands at $498.5 million. The company's, Q4 earnings came out yesterday. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock moved upwards by 64.95% to $3.63. The market value of their outstanding shares is at $368.2 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares increased by 42.1% to $0.68. The company's market cap stands at $6.7 million. </li>
<li>Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) shares rose 36.92% to $3.3. The market value of their outstanding shares is at $134.6 million. </li>
<li>Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) shares moved upwards by 32.22% to $2.98. The company's market cap stands at $651.6 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock moved upwards by 28.42% to $3.75. The company's market cap stands at $72.4 million. As per the press release, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock declined by 51.8% to $0.48 during Tuesday's regular session. The company's market cap stands at $1.7 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares decreased by 18.23% to $3.68. The company's market cap stands at $44.9 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) stock decreased by 18.04% to $2.0. The market value of their outstanding shares is at $70.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 17.11% to $2.81. The company's market cap stands at $3.4 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) stock decreased by 17.03% to $7.02. The company's market cap stands at $352.0 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 15.37% to $0.83. The company's market cap stands at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

TKNO

WORX

12 Health Care Stocks Moving In Tuesday's Intraday Session

Journey Medical shares are trading lower. The company reported Q4 financial results.

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported its Q4 earnings results on Thursday, March 21, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Journey Medical beat estimated earnings by 138.0%, reporting an EPS of $0.03 versus an estimate of $-0.08.
Revenue was down $709 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $1.14 which was followed by a 10.0% increase in the share price the next day.
Here's a look at Journey Medical's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.33</td>
<td>-0.45</td>
<td>-0.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.99</td>
<td>-0.04</td>
<td>-0.30</td>
<td>-0.17</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>16.88M</td>
<td>14.81M</td>
<td>16.18M</td>
<td>16.58M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>34.54M</td>
<td>17.17M</td>
<td>12.21M</td>
<td>15.97M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Journey Medical <a href="https://www.benzinga.com/quote/DERM/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Journey Medical Q4 Earnings

Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.08) by 137.5 percent. The company reported quarterly sales of $15.257 million which beat the analyst consensus estimate of $15.061 million by 1.30 percent. This is a 4.44 percent decrease over sales of $15.966 million the same period last year.

Journey Medical Q4 2023 Adj EPS $0.03 Beats $(0.08) Estimate, Sales $15.257M Beat $15.061M Estimate

Lake Street analyst Thomas Flaten maintained a Buy rating on Journey Medical Corp (DERM – Research Report) today and set a price target of $9.00. T...

Journey Medical Corp (DERM) Gets a Buy from Lake Street

Lake Street analyst Thomas Flaten reiterated a Buy rating on Journey Medical Corp (DERM – Research Report) today and set a price target of $9.00. T...

Lake Street Keeps Their Buy Rating on Journey Medical Corp (DERM)

Alliance Global Partners analyst Scott Henry raised the firm's price target on Journey Medical (DERM) to $11 from $8.50 and reiterated a Buy rating...

Journey Medical price target raised to $11 from $8.50 at Alliance Global Partners

Journey gets FDA okay for Emrosi, releases preliminary Q3 earnings report

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Reports Q3 revenue $14.63M, consensus $14.39M. Claude Maraoui, Journey Medical's (DERM) Co-Founder, President and Chief Executive Officer, said, "G...

Journey Medical reports Q3 EPS (12c), consensus (15c)

Journey Medical GAAP EPS of -$0.12 beats by $0.03, revenue of $14.63M beats by $0.24M

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Journey Medical Corp (DERM – Research Report), with a price t...

Lake Street Remains a Buy on Journey Medical Corp (DERM)

Roth MKM raised the firm's price target on Fortress Biotech (FBIO) to $15 from $13 and keeps a Buy rating on the shares after its Q3 results. The c...

Fortress Biotech price target raised to $15 from $13 at Roth MKM

Virtual Meeting to be held on November 21 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Journey Medical management to meet virtually with B. Riley

ALKS

APLS

CRBP

ELAB

FBIO

NKTR

RPRX

TKPHF

VRCA

VRNA

Press Releases

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Health Care

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

SWK Holdings Provides Portfolio Update

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Comments

Journey Medical

Journey Medical (DERM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga